Literature DB >> 32004931

3,3-Dimethyl-1-butanol attenuates cardiac remodeling in pressure-overload-induced heart failure mice.

Guangji Wang1, Bin Kong1, Wei Shuai1, Hui Fu1, Xiaobo Jiang1, He Huang2.   

Abstract

Trimethylamine N-oxide (TMAO) is closely related to cardiovascular diseases, particularly heart failure (HF). Recent studies shows that 3,3-dimethyl-1-butanol (DMB) can reduce plasma TMAO levels. However, the role of DMB in overload-induced HF is not well understood. In this research study, we explored the effects and the underlying mechanisms of DMB in overload-induced HF. Aortic banding (AB) surgery was performed in C57BL6/J mice to induce HF, and a subset group of mice underwent a sham operation. After surgery, the mice were fed with a normal diet and given water supplemented with or without 1% DMB for 6 weeks. Cardiac function, plasma TMAO level, cardiac hypertrophy and fibrosis, expression of inflammatory, electrophysiological studies and signaling pathway were analyzed at the sixth week after AB surgery. DMB reduced TMAO levels in overload-induced HF mice. Adverse cardiac structural remodeling, such as cardiac hypertrophy, fibrosis and inflammation, was elevated in overload-induced HF mice. Susceptibility to ventricular arrhythmia also significantly increased in overload-induced HF mice. However, these changes were prevented by DMB treatment. DMB attenuated all of these changes by reducing plasma TMAO levels, hence negatively inhibiting the p65 NF-κB signaling pathway and TGF-β1/Smad3 signaling pathway. DMB plays an important role in attenuating the development of cardiac structural remodeling and electrical remodeling in overload-induced HF mice. This may be attributed to the p65 NF-κB signaling pathway and TGF-β1/Smad3 signaling pathway inhibition.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3,3-Dimethyl-1-butanol; Electrical remodeling; Heart failure; Structural remodeling; Trimethylamine N-oxide

Year:  2020        PMID: 32004931     DOI: 10.1016/j.jnutbio.2020.108341

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  9 in total

Review 1.  The Emerging Role of the Gut Microbiome in Cardiovascular Disease: Current Knowledge and Perspectives.

Authors:  Panagiotis D Papadopoulos; Christina Tsigalou; Pipitsa N Valsamaki; Theocharis G Konstantinidis; Chrysoula Voidarou; Eugenia Bezirtzoglou
Journal:  Biomedicines       Date:  2022-04-20

Review 2.  Gut Microbiota and Cardiovascular Disease.

Authors:  Marco Witkowski; Taylor L Weeks; Stanley L Hazen
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

Review 3.  The Gut in Heart Failure: Current Knowledge and Novel Frontiers.

Authors:  Antonella Gallo; Noemi Macerola; Angela Maria Favuzzi; Maria Anna Nicolazzi; Antonio Gasbarrini; Massimo Montalto
Journal:  Med Princ Pract       Date:  2022-01-28       Impact factor: 2.132

Review 4.  Implication of Gut Microbiota in Cardiovascular Diseases.

Authors:  Wenyi Zhou; Yiyu Cheng; Ping Zhu; M I Nasser; Xueyan Zhang; Mingyi Zhao
Journal:  Oxid Med Cell Longev       Date:  2020-09-26       Impact factor: 6.543

Review 5.  The Gut Microbial-Derived Metabolite Trimethylamine N-Oxide and Atrial Fibrillation: Relationships, Mechanisms, and Therapeutic Strategies.

Authors:  Rui Huang; Li Yan; Yuhua Lei
Journal:  Clin Interv Aging       Date:  2021-11-30       Impact factor: 4.458

Review 6.  Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives.

Authors:  Oxana M Drapkina; Adel A Yafarova; Anastasia N Kaburova; Anton R Kiselev
Journal:  Biomedicines       Date:  2022-08-19

7.  Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic Diseases.

Authors:  Fernando F Anhê; Benjamin A H Jensen; Lais Rossi Perazza; André Tchernof; Jonathan D Schertzer; André Marette
Journal:  J Lipid Atheroscler       Date:  2021-02-09

Review 8.  Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids.

Authors:  Qinyu Li; Bing Gao; Bateer Siqin; Qian He; Ru Zhang; Xiangxi Meng; Naiheng Zhang; Na Zhang; Minhui Li
Journal:  Front Pharmacol       Date:  2021-06-16       Impact factor: 5.810

9.  Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease.

Authors:  Qing Fang; Binjie Zheng; Na Liu; Jinfeng Liu; Wenhui Liu; Xinyi Huang; Xiangchang Zeng; Lulu Chen; Zhenyu Li; Dongsheng Ouyang
Journal:  Front Physiol       Date:  2021-06-16       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.